FOR PATIENTS & SURVIVORS WITH HPV+ CANCER

Know More.
Worry Less.

If you have been diagnosed with or treated for HPV+ head & neck cancer or anal cancer, you know how unsettling uncertainty can feel.

HPV+ Cancer Detection with a Simple Blood Draw.

The NavDx^® test is the first and most clinically validated liquid biopsy (a highly sensitive blood test) that can detect HPV+ head & neck cancer and HPV+ anal cancer, in many cases months before it shows up in clinical exams or on imaging. With a simple, non-invasive blood draw, the NavDx test can help your Provider uncover important information about your cancer status throughout your care journey, from before treatment begins through long-term monitoring after treatment ends.

The NavDx test is not an HPV test; it does not detect active HPV infection that is unrelated to HPV+ cancers. It is also not a screening tool for HPV-related pre-cancers, like the Pap test, which is used to screen for cervical cancer.

How does the NavDx test work?

Cancer cells release tiny fragments of their DNA into the bloodstream as a normal part of their lifecycle. These fragments, called circulating tumor DNA (ctDNA), can be detected in a blood sample. The NavDx test is designed to measure a very particular type of ctDNA called tumor tissue modified viral HPV DNA (TTMV-HPV DNA).

TTMV®-HPV DNA is a biomarker—a molecule that can be objectively measured in a laboratory test to provide important information about your cancer status. The NavDx test is highly sensitive and specifically engineered to find and measure TTMV-HPV DNA fragments in your blood.

The test is backed by strong clinical evidence with over 120,000 tests performed on nearly 40,000 patients…and counting.

What is a TTMV Score?

A TTMV Score is the unique result generated by the NavDx test. It reflects the number and size of TTMV-HPV DNA fragments detected in your blood sample. Tracking changes in your TTMV Score over time gives your Provider meaningful information about your HPV+ cancer status.

Seeing Cancer Sooner.

What makes the NavDx test different from standard surveillance methods, like physical exams and imaging, is what it can detect—and how small. While physical exams and imaging find tumors measured in centimeters or millimeters, the NavDx test looks for fragments of HPV+ cancer DNA in the blood, measured in base pairs. Wonder how big (or small) that actually is? Take a look at this comparison chart:

When is the NavDx Test Used and What Can It Tell Me and My Provider?

The NavDx test can be used across the HPV+ cancer care journey. Your Provider will determine which use, or combination of uses, is right for your specific situation.

Pre-Treatment

Confirm HPV+ etiology
Identify the tumor HPV genotype

View Pre-Treatment Guidance

During Treatment

TTMV-HPV DNA clearance kinetics during CRT
Identify molecular residual disease

View During Treatment Guidance

Surveillance

The most common use of NavDx testing

Detect recurrence earlier with high-confidence positive results
Provide reassurance with high-confidence negative results

View Surveillance Guidance

A pre-treatment test is not required to use the NavDx test at other points in the care journey. Monitoring with the NavDx test can be started at any time.

Post-Treatment Surveillance: Earlier Detection When It Matters Most.

Post-treatment surveillance is the most common use of the NavDx test. Published studies show that routine NavDx testing can detect recurrence earlier than standard surveillance methods, such as physical exams, scopes, and imaging, which have critical limitations that can reduce their effectiveness. But the NavDx test detects cancer by finding fragments of its DNA in your blood, so it has the potential to find evidence of HPV+ cancer regardless of tumor size or where in your body it may be, even in patients with no symptoms whose clinical exams and imaging were clear.

Earlier detection matters because when recurrence is found sooner, the chance for successful treatment is greatest, more options may be available, and patients may be spared from more aggressive therapies. In some cases, targeted approaches, such as removing a small nodule or using limited directed radiation, may be possible in place of full chemoradiation.

Greater Assurance and Peace of Mind.

After completing cancer treatment, fear of recurrence is one of the most common concerns patients face. Studies show that up to 25% of HPV+ head & neck cancer patients and up to 30% of HPV+ anal cancer patients may experience a recurrence.

For many patients, the reassurance of a negative NavDx test result is just as valuable as catching recurrence early. Because NavDx testing is highly accurate, a negative result means a very strong likelihood that there was no detectable disease at the time of testing. That can also mean less worry between follow-up appointments.

A negative NavDx result can provide greater peace of mind, higher confidence in your health status, and less fear of recurrence, so you can focus on living your life.

Getting Started is Easy.

The NavDx test requires only a simple blood draw. No special preparation is needed. Your blood sample can be collected at your Provider’s office or care facility. You can also use NavDx-Arranged Phlebotomy to have your blood drawn at:

A local walk-in clinic near you
Your home, workplace, or other convenient location

With NavDx-Arranged Phlebotomy, the NavDx test is available everywhere blood can be drawn in the United States. We will even reach out as your next testing period approaches to help you stay on schedule.

Learn More

Head & Neck Cancer P A T I E N T S

HPV+ Head & Neck Cancer.

Learn About NavDx Testing and Head & Neck Cancer

Anal Cancer P A T I E N T S

HPV+ Anal Cancer.

Learn About NavDx Testing and Anal Cancer

Coverage and Financial Assistance.

NavDx testing is covered by a growing number of commercial insurance companies, as well as Medicare for specific indications. Financial assistance is available to those who qualify.